Introduction {#Sec1}
============

Gestational diabetes (GDM) is traditionally defined as carbohydrate intolerance with its onset or the first recognition in pregnancy \[[@CR1]\], although more recent definitions explicitly exclude pre-existing type 2 diabetes \[[@CR2]\]. It is one of the most common adverse conditions of pregnancy. Its incidence has generally been reported to be rising in most populations, usually in line with the increasing prevalence of maternal obesity \[[@CR3]\]. Other major risk factors for GDM include having a previous history of it or having previously given birth to a macrosomic baby, a family history of GDM and/or type 2 diabetes, increased maternal age, increased gestational weight gain, genetics, multiparity and ethnic factors \[[@CR4]\], not all of which can explain the tempo of the rising incidence. As GDM increases the risk of short- and long-term adverse complications for both the mother and her unborn child (including macrosomia, pre-eclampsia, childhood obesity and the metabolic syndrome in the mother \[[@CR5]\]) and may contribute to the diabetes pandemic \[[@CR6]\], a thorough understanding of its pathogenesis is essential.

With the apparent worldwide rise in the prevalence of GDM \[[@CR7]\], paralleling the increasing prevalence of female obesity \[[@CR8]\] of note is the temporal and potentially mechanistic links that obesity has with global warming \[[@CR9]\]. Therefore, another factor that could explain at least part of the increased incidence of GDM is exposure to raise or rising ambient temperatures in certain populations \[[@CR10]--[@CR12]\]. Following this, some studies have reported seasonal variations in the incidence of GDM \[[@CR13]--[@CR17]\], although this has not been observed in all populations or climates \[[@CR18], [@CR19]\]. In this study we investigated whether there were temporal and seasonal trends in GDM incidence in our single-centre population from Cambridge, UK, which recruited pregnant women between 2001 and 2009. We then investigated what may have mediated any trends. Although relating to a decade ago, this seemed reasonable given that GDM was already becoming more prevalent by this time in several different populations \[[@CR20]--[@CR25]\].

Materials and methods {#Sec2}
=====================

Cambridge Baby Growth Study {#Sec3}
---------------------------

The prospective, longitudinal Cambridge Baby Growth Study (CBGS) was established as an observational cohort initially covering pregnancy, birth and infancy \[[@CR26]\]. 2229 mothers, all over 16 years of age, were recruited when attending early pregnancy ultrasound clinics at the Rosie Maternity Hospital, Cambridge, UK, between April 2001 and March 2009. A total of 571 of these mothers withdrew prior to the birth of their infant. Most of the clinical characteristics of the study participants were collected either during nurse-led interviews or by questionnaire with the exception of offspring birth weight, gestational age and date of birth, which were compiled from hospital notes. In this cohort, 95.3% of the offspring were white, 1.7% were Asian, 1.3% were black (African or Caribbean) and 1.7% were other ethnicities (mainly mixed race), reflective of the population served by the Rosie Maternity Hospital.

Ethics {#Sec4}
------

The Cambridge Baby Growth Study was approved by the Cambridge Local Research Ethics Committee, Addenbrooke's Hospital, Cambridge, UK (00/325). All procedures followed were in accordance with the institutional guidelines. Written informed consent was obtained from all the study participants.

Oral glucose tolerance test and gestational diabetes diagnostic criteria {#Sec5}
------------------------------------------------------------------------

At a median (inter-quartile range) of 28.4 (28.1--28.7) weeks gestation, 1074 of the CBGS mothers underwent a 75-g oral glucose tolerance test (OGTT) after fasting overnight \[[@CR27]\]. Venous blood was collected just prior to and 60 min after the glucose load was administered for the measurement of plasma glucose, insulin and c-peptide concentrations. 120 min plasma glucose concentrations were only measured from May 2007 onwards so were not used in this study to define GDM (only 7% of UK women with GDM receive a diagnosis based solely on the 120-min measurement in any case \[[@CR28]\]). The International Association of Diabetes in Pregnancy Study Groups (IADPSG) thresholds for 0 and 60 min. OGTT glucose concentrations (i.e. ≥ 5.1 and 10.0 mmol/L, respectively \[[@CR29]\]) were used to define the presence of GDM.

Assays {#Sec6}
------

All biochemical kit-based assays were run according to the manufacturer's instructions. Glucose concentrations were measured using a routine glucose oxidase-based method. OGTT plasma insulin concentrations were measured by ELISA (Dako UK Ltd., Ely, Cambs, UK). Intra-assay imprecision (CV) was 4.3% at 14 mU/L (82 pmol/L), 3.0% at 67 mU/L (402 pmol/L) and 5.7% at 151 mU/L (907 pmol/L). Equivalent inter-assay imprecision was 4.3, 5.1 and 5.4%, respectively. C-peptide concentrations were also measured by ELISA (DSL Labs., London, UK). Intra-assay imprecision was 2.8% at 1.3 ng/mL (0.43 nmol/L) and at 4.4 ng/mL (1.47 nmol/L) and 3.2% at 8.4 ng/mL (2.80 nmol/L). Equivalent inter-assay imprecision was 15.7, 7.8 and 10.3%, respectively.

Calculations {#Sec7}
------------

The maternal body mass index (BMI) was calculated as the pre-pregnancy weight divided by the height squared. Insulin sensitivity and pancreatic β-cell function were estimated using the homeostasis model assessment (HOMA S and B, respectively), calculated using the week 28 fasting circulating glucose and insulin (or c-peptide) concentrations and the online HOMA2 calculator (available at <https://www.dtu.ox.ac.uk/homacalculator/>) \[[@CR30]\]. For this study, HOMA values were calculated using both insulin and c-peptide concentrations separately, and where mentioned in this manuscript refer to insulin-derived values unless stated otherwise. Insulin secretion (for a given insulin sensitivity) was assessed in terms of the insulin disposition index, calculated as the change in insulin concentrations over the first hour of the OGTT divided by the change in glucose concentrations, all divided by the reciprocal of the fasting insulin concentration. An equivalent disposition index was also calculated using plasma c-peptide concentrations. The index of multiple deprivation was derived and imputed from the postcode of the participants' home addresses as described \[[@CR31]\].

Statistical analysis {#Sec8}
--------------------

The present analysis was restricted to those 1074 pregnancies where the women underwent OGTTs (thereby, excluding women with pre-existing type 1 diabetes) with 0 and 60 min plasma glucose concentrations available to us. Data were logarithmically transformed prior to analyses if their distributions were positively skewed. Temporal trends, adjusted for seasonal trends, were tested for using the cosinor regression model in R (version 3.5.2; The R Project for Statistical Computing, Vienna, Austria) deploying the package cosinor (version 1.1, available at <http://github.com/sachsmc/cosinor>) which assumes a sinusoidal seasonal pattern over a longitudinal period, in this case OGTT season and year of analysis, respectively. The season was based on the month the OGTT was performed using Northern Meteorological seasons: winter (December--February), spring (March--May), summer (June--August) and autumn (fall) (September--November). Further analysis was performed by standard logistic (for binary variables) or linear (for continuous variables whose model residuals using untransformed or transformed data were normally distributed) regression. Nonparametric regression (to fit linear regression models that included the index of multiple deprivation due to the lack of normal distribution of the residuals in standard linear regression models) was performed by means of the Siegel repeated medians procedure (deploying the R package mblm, version 0.12.1, available at <https://cran.r-project.org/web/packages/mblm/index.html>). Categorical analysis was performed using the *χ*^2^ test. Unless stated, all the other statistical analyses were performed using Stata (version 13.1; Stata Corp., from Timberlake Consultants Ltd., Richmond, Surrey, UK). Statistical significance was assumed at *p* \< 0.05 throughout.

GDM risk factors assessed as above for association with year of testing included: BMI, pregnancy weight gain, maternal age, offspring birth weight, parity and index of multiple deprivation (as continuous variables), and offspring sex and multifetal pregnancy (as categorical/binary data).

Results {#Sec9}
=======

Characteristics of the study population {#Sec10}
---------------------------------------

With the exception of a slight increase in parity and a reduced proportion of smokers, those women who were included in the analysis were representative of the Cambridge Baby Growth Study as a whole (Table [1](#Tab1){ref-type="table"}). Variables that were not detectably different included GDM prevalence, fasting glucose and insulin concentrations, pre-pregnancy BMI and maternal age.Table 1Characteristics of those Cambridge Baby Growth Study participants who were included in the current analysis and those that were notCharacteristicIncludedNot included*p* valueMother's age at the birth of her baby (years)33.4 (33.1, 33.6) (*n* = 901)33.8 (33.4, 34.2) (*n* = 434)0.06Parity (*n*, of increasing parity)489/373/122/32/6/3228/267/93/29/2/31.2 × 10^−4^GDM110 yes, 967 no1 yes, 6 no0.5OGTT fasting glucose concentration (mmol/L)4.3 (4.3, 4.4) (*n* = 1073)4.2 (3.7, 4.6) (*n* = 6)0.5OGTT fasting insulin concentration (pmol/L)45.5 (44.0, 47.0) (*n* = 1053)46.4 (41.3, 52.1) (*n* = 83)0.7Pre-pregnancy BMI (kg/m^2^)23.4 (23.2, 23.7) (*n* = 830)23.3 (22.9, 23.7) (*n* = 357)0.6Index of multiple deprivation8.9 (8.7, 9.1) (*n* = 1068)9.0 (8.7, 9.2) (*n* = 585)0.9Maternal highest qualification (category 3/4/5)80/133/35833/52/1340.9Sex of baby (*n* males/females)535/492320/3070.7Baby's birth weight (kg)^a^3.483 (3.454, 3.514) (*n* = 830)3.458 (3.412, 3.504) (*n* = 357)0.4Gestational age at birth of baby (weeks)39.8 (39.7, 39.9) (*n* = 1029)39.7 (39.6, 39.8) (*n* = 628)0.1Reported smoking during pregnancy (*n* yes/no)40/98746/5822.0 × 10^−3a^Adjusted for maternal pre-pregnancy BMI, gestational age at birth, sex of baby and parity. Data are either number of participants or mean (95% confidence interval)

Temporal Trends of GDM Incidence and OGTT Glucose Concentrations {#Sec11}
----------------------------------------------------------------

The overall prevalence of GDM in this population was 10.1% (108/1071). Cosinor analysis showed a significant temporal effect associated with the year of analysis \[0.014 (0.005, 0.022) proportional increase per year, *p* = 2.1 × 10^−3^\], with a trend for the incidence of GDM increasing through the years 2001--2009 (Fig. [1](#Fig1){ref-type="fig"}). This finding was confirmed by logistic regression \[odds ratio (OR) 1.2 (1.1, 1.3) per year, *p* = 2.8 × 10^−3^, *n* = 1049\], even when the small numbers of participants collected in 2009 were excluded from the analysis \[OR 1.2 (1.1, 1.3) per year, *p* = 3.3 × 10^−3^, *n* = 1040\]. There was, however, no significant association of GDM with seasonality \[amplitude: 9.8 (− 14.7, 34.3), *p* = 0.4; acrophase − 0.6 (− 3.0, 1.9), *p* = 0.7\] (Fig. [1](#Fig1){ref-type="fig"}). Cosinor analysis revealed no significant association of the OGTT fasting glucose concentration with the year \[0.009 (− 0.007, 0.025) mmol/L per year, *p* = 0.3\] or with seasonality \[amplitude: 21.3 (− 24.1, 66.6), *p* = 0.4; acrophase − 0.4 (− 2.4, 1.6), *p* = 0.7\]. Conversely there was a temporal trend with the OGTT 60-min glucose concentrations \[0.117 (0.067, 0.166) mmol/L per year, *p* \< 1 × 10^−4^\] (Fig. [2](#Fig2){ref-type="fig"}), a finding which was confirmed by linear regression (*β*′ = 0.147, *p* = 1.3 × 10^−6^, *n* = 1071), without a seasonal effect \[amplitude: 53.7 (− 84.1, 191.5), *p* = 0.4; acrophase − 0.9 (− 3.4, 1.7), *p* = 0.5\].Fig. 1**a** Proportion of women with GDM by the season of the year, following an OGTT around week 28 of pregnancy, adjusted for year of analysis. Data are means (95% confidence intervals). Analysing this data categorically (taking no account of the recurring order of the seasons) showed no association between GDM and season of the year (*χ*^2^ = 2.2, *p* = 0.5). **b** Proportion of women with GDM by the year of testing, following an OGTT around week 28 of pregnancyFig. 2Dot plot of OGTT 60-min glucose concentrations by the year of OGTT testing. The bars represent the limits of the inter-quartile range of the values represented by the dots

Temporal trends of indices of insulin sensitivity and secretion {#Sec12}
---------------------------------------------------------------

Insulin-derived HOMA S was positively associated with the year of testing \[0.016 (0.001, 0.032) per year, *p* = 0.04\] but not with the season of testing \[amplitude: 21.7 (− 20.8, 64.1), *p* = 0.3; acrophase 1.3 (− 0.7, 3.4), *p* = 0.2\], a finding which was confirmed by linear regression (*β*′ = 0.080, *p* = 9.1 × 10^−3^, *n* = 1049). This association was still evident if adjusting for GDM (*p* = 3.4 × 10^−4^, *n* = 1049) or by only including women who were classified as not having GDM (*p* = 1.2 × 10^−3^; *n* = 947). However, the association disappeared if it were tested using c-peptide-derived HOMA S, in a smaller number of women (*β*′ = 0.014, *p* = 0.7, *n* = 929).

Whilst still having a lack of association with seasonality \[amplitude: 20.9 (− 6.4, 48.2), *p* = 0.1; acrophase 0.6 (− 0.7, 1.9), *p* = 0.4\], in contrast to the findings with HOMA S, insulin-derived HOMA B was negatively associated with year of testing \[− 0.015 (− 0.025, − 0.005) per year, *p* = 3.0 × 10^−3^\]. This association was confirmed by linear regression (*β*′ = − 0.104, *p* = 7.0 × 10^−4^, *n* = 1049). Again, it was still evident if adjusting for GDM (*p* = 1.2 × 10^−3^, *n* = 1049) or if only including women without GDM (*p* = 1.2 × 10^−3^; *n* = 947). This association was still present if it were tested using c-peptide-derived HOMA B, in a smaller number of women (*β*′ = − 0.073, *p* = 0.03, *n* = 929).

Similar to the results for HOMA B, the insulin disposition index was negatively associated with year of testing \[− 0.036 (− 0.060, − 0.013) per year, *p* = 3.0 × 10^−3^\], a finding which was confirmed by linear regression (*β*′ = − 0.091, *p* = 3.8 × 10^−3^, *n* = 1000). This association was still evident if adjusting for GDM (*p* = 0.03; *n* = 1000) or if only including women without GDM (*p* = 0.03; *n* = 905). The insulin disposition index was not, however, associated with season of testing \[amplitude: 26.0 (− 38.5, 90.5), *p* = 0.4; acrophase 1.1 (− 1.5, 3.7), *p* = 0.4\]. The c-peptide disposition index was also negatively associated with year of testing (*β*′ = − 0.074, *p* = 0.03, *n* = 882).

Associations of the year of analysis with potential risk factors {#Sec13}
----------------------------------------------------------------

The year of analysis was not associated with either the maternal BMI (*β*′ = 0.006, *p* = 0.9, *n* = 827) or pregnancy weight gain (*β*′ = − 0.047, *p* = 0.2, *n* = 614). Neither was it associated with maternal age (*β*′ = − 0.016, *p* = 0.6, *n* = 898) or parity (*β*′ = 0.007, *p* = 0.8, *n* = 1022) in this population. There was no association between the year of analysis and the proportion of male babies (*χ*^2^ = 4.9, *p* = 0.8, *n* = 1024), birth weight of the babies (*β*′ = − 0.023, *p* = 0.4, *n* = 824; adjusted for gestational age at birth, mother's BMI, parity and sex) or the odds of a pregnancy being multifetal \[OR 1.0 (0.9, 1.2), *p* = 0.9, *n* = 1071\]. One potential confounder that year of analysis was modestly albeit highly significantly associated with, and the index of multiple deprivation \[0.191 (0.138, 0.257) units per year, *p* = 4.6 × 10^−10^, *n* = 1068\] (Fig. [3](#Fig3){ref-type="fig"}) was itself not directly associated with GDM \[OR 1.0 (1.0, 1.1) per unit increase in the index, *p* = 0.6, *n* = 1032\]. There was still a significant relationship between the index of multiple deprivation and the year in the reduced number of 955 women for whom HOMA modelling was available \[0.174 (0.118, 0.237) units per year, *p* = 5.2 × 10^−8^\]. In these women, the index of multiple deprivation was significantly positively associated with HOMA B \[0.756 (0.376, 1.143) per unit, *p* = 6.1 × 10^−5^; Fig. [3](#Fig3){ref-type="fig"}\] but not with HOMA S \[− 0.394 (− 0.967, 0.197) per unit, *p* = 0.2\] or the insulin disposition index \[43.6 (− 53.8, 150.8) per unit, *p* = 0.4\].Fig. 3Dot plots of **a** the index of multiple deprivation by year of testing and **b** HOMA B values by the index of multiple deprivation. The lines of best fit (minimising the distance between the line and median values) were calculated using the Siegel repeated medians procedure

Discussion {#Sec14}
==========

In this analysis, there was a strong trend for the incidence of GDM increasing as recruitment to the cohort progressed between 2001 and 2009. Trends over a similar period of time have also been observed in populations in Canada \[[@CR21]\], the USA \[[@CR22], [@CR24]\], Israel \[[@CR23]\] and Germany \[[@CR25]\]. The worldwide increased incidence at that time appeared to be independent of ethnicity \[[@CR20]\] despite this being a major factor associated with GDM risk \[[@CR4]\]. In our population, the increased incidence of GDM was associated with reductions in HOMA B and the insulin disposition index (rather than HOMA S). Whilst a temporal trend in these factors could relate to changes in the performance of the insulin and glucose assays that were used over time, we used the same assays for these analyses throughout this time period and the performance characteristics of the insulin assay matched those of similar assays available at the time \[[@CR32]\]. Given that the performance of the glucose assay did not change over this time, the fact that the associations with HOMA B and the disposition index persisted if they were calculated using c-peptide rather than insulin concentrations suggests that these associations were physiological rather than assay related. The temporal increase in GDM incidence in our population therefore appeared to relate to reductions in insulin secretion rather than sensitivity (indeed insulin-derived HOMA S actually increased over the period of recruitment, albeit this association was not evident when c-peptide concentrations were used to calculate HOMA S in a smaller number of women).

The temporal increase in GDM incidence was clearly environmentally mediated as its tempo was too fast for a genetic change. In investigating its potential causes and the reduced insulin secretion, we could not find parallel increases in BMI (itself strongly associated with GDM and partially driving the link between factors such as early age at menarche and increased GDM risk \[[@CR33]\] as has previously been observed in our population \[[@CR34]\]), pregnancy weight gain, maternal age or smoking. There was, however, a significant temporal trend of increasing deprivation in the study (in a population that was generally less-deprived than the national average \[[@CR26]\]) although deprivation itself was not associated with GDM. There was a modest albeit highly significant positive association between the index of multiple deprivation and insulin-derived HOMA B. This suggests that in the absence of direct associations with HOMA S or GDM risk, as the deprivation index went up pancreatic β-cell function might have had to increase slightly to maintain glucose homeostasis. Due to the lack of direct association between the deprivation index and GDM despite the temporal trend, it is possible, however, that as yet unidentified confounder(s) related to deprivation, such as factors connected with diet \[[@CR35]\] and/or exercise \[[@CR36]\], could have contributed to the temporal increase in GDM incidence. This would be consistent with studies where associations between GDM and deprivation, lower socioeconomic status or lower social class were reported \[[@CR25], [@CR37], [@CR38]\] although such associations have not been found in every study \[[@CR39]\]. An alternative explanation for the temporal trend in deprivation in the present study is that it may just reflect unintentional secular patterning in study recruitment or uptake.

Although we observed a temporal trend of increasing GDM incidence as the decade progressed in this analysis, we could not find a seasonal trend. This is despite seasonal trends in GDM previously have been observed in populations in Sweden \[[@CR13]\], Australia \[[@CR14], [@CR15]\], Italy \[[@CR16]\] and Greece \[[@CR17]\]. However, of the populations tested before where no such trend was observed \[[@CR18], [@CR19]\], one of these was also in the UK \[[@CR19]\] so our lack of seasonal trend may relate to climate or other environmental factors specific to the UK. GDM is known to be a heterogeneous disease \[[@CR40]\], and the degree of that heterogeneity may be smaller when comparing two populations of the same nationality and ethnic mix. Alternatively, whilst at least one of the studies that found a seasonal trend used a very similar analysis technique to the one that we used \[[@CR15]\], other studies used analysis of variance or categorical/ordinal analyses which did not account for the recurring nature of the seasons or adjust for longer-term temporal trends \[[@CR13], [@CR14], [@CR16], [@CR17]\] so differences from our results may relate to this.

The strengths of our prospective study include the fact that we used cosinor analysis to adjust linear temporal trends for separate potential seasonal effects, unlike some of the other studies in this area. In addition, we had third trimester OGTT data from all the study participants and so we were able to investigate whether temporal trends in GDM incidence were related to changes in insulin sensitivity or secretion, a level of detail that is rarely available in larger surveys. We calculated HOMAs using both insulin and c-peptide concentrations so that detectable temporal trends were less likely to have resulted from drift in assay performance. In addition to its strengths, the study does have a number of limitations, however. Firstly, this Cambridge cohort may not fully reflect the UK population as a whole particularly in relation to ethnic mix and smoking prevalence \[[@CR25]\], although this means that there was probably less confounding due to ethnic effects and other factors related to the heterogeneity of GDM \[[@CR40]\]. Secondly, although the study was fairly large given the level of detail that was collected, it was smaller than temporal studies of large surveys (e.g. \[[@CR41]\]), and therefore, the proportion of women who develop GDM in our study may be a little unrepresentative of the whole population. This could partially account for the large magnitude of the increased GDM incidence over the course of the recruitment period in our study. This limitation is offset by the level of detail that was collected for each of the study participants, however, which allowed us to relate temporal changes in the prevalence of GDM to changes in insulin secretion, a finding which has not been attempted in larger studies. Thirdly, another limitation is that we did not record family histories of GDM and type 2 diabetes, major risk factors for GDM \[[@CR4]\]. The final limitation of our study is that the insulin (and c-peptide) disposition index was not calculated using 30 min. OGTT glucose and insulin concentrations like usual, but using 60 min concentrations instead. Although comparing OGTT results from our study with those more commonly from intravenous GTTs, its use has been deemed acceptable at least for the insulinogenic element of the disposition index \[[@CR42]\].

In conclusion, we observed a temporal but not seasonal trend for an increasing incidence of GDM in Cambridge Baby Growth Study pregnancies from the years 2001--2009. This was associated with reductions in indices of insulin secretion rather than insulin sensitivity. Although we do not know what caused these changes, it does not appear to relate to changes in maternal obesity or age. Factors relating to deprivation offer potential explanations.
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